Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 61Thoracic 8Gynecologic 5Head & Neck 3Genitourinary 3Dermatologic 3Other solid neoplasm 2Other hematologic neoplasm 2Lymphoid 2Endocrine 2CNS 2Breast 2Tumor-Agnostic 1Sarcoma 1NET 1Myeloid 1

Conditions

Neuroendocrine Tumors 1Carcinoma, Neuroendocrine 1

Interventions

Everolimus 23pasireotide 14lutetium Lu 177 dotatate 10Octreotide 10lanreotide 9surufatinib 8Carboplatin 8Paclitaxel 7pembrolizumab 5amino-acid, glucose, and electrolyte solution 5Thyrotropin Alfa 5Sunitinib 5Nivolumab 5Injections 53-Iodobenzylguanidine 5relacorilant 4fosbretabulin 4Temozolomide 4Fulvestrant 4Etoposide 4Data Collection 4Cisplatin 4vandetanib 3selpercatinib 3dabrafenib 3anlotinib 3Mifepristone 3Lutetium-177 3Lutetium 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × IFL protocol × Endocrine × Clear all
NCT07595913 2026-05-19

A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Not yet recruiting
240 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT05879055 2024-12-19

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Biotheus Inc.

Phase 2 Recruiting
60 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡